Tvardi Therapeutics Q2 net loss $6.5 million; cash falls to $15.8 million
Tvardi Therapeutics reported a second-quarter 2026 net loss of $6.5 million, compared with net income of $4.2 million a year earlier, which included a $12.7 million non-cash gain. The company also reported topline healthy volunteer results for TTI-109, selected ulcerative colitis as its initial indication, and said its cash runway reaches the HCC readout in the third quarter of 2027, with additional funding needed to advance TTI-109 in UC.
Key points
- Net loss of $6.5 million for the quarter ended June 30, 2026, versus net income of $4.2 million in the same period of 2025; basic and diluted loss per share was $(0.69).
- Research and development expenses fell to $4.0 million from $5.8 million, and general and administrative expenses fell to $2.6 million from $3.1 million.
- Cash, cash equivalents and short-term investments were $15.8 million at June 30, 2026, down from $30.8 million at December 31, 2025.
- A KOL webinar on TTI-109 in UC is scheduled for August 19, 2026; the UC trial start is planned for 2027, subject to IND clearance and additional funding.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.